1. Łodyga M, Eder P, Gawron-Kiszka M, et al. Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2021; 16: 257-96.
2.
Eder P, Łodyga M, Gawron-Kiszka M, et al. Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Gastroenterology Rev 2023;18: 1-42.
3.
Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis 2022; 16: 2-17.
4.
Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020; 14: 4-22.
5.
Atlas kliniczno-patologiczny nieswoistych chorób zapalnych jelit. Wejman J, Bartnik W, editors. Termedia Poznan 2011.
6.
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol 2014; 20: 91-9.
7.
Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res 2019; 2019: 7247238.
8.
Holleran G, Lopetuso L, Ianiro G, et al. Gut microbiota and inflammatory bowel disease: so far so gut! Minerva Gastroenterol Dietol 2017; 63: 373-84.
9.
Qiu P, Ishimoto T, Fu L, et al. The gut microbiota in inflammatory bowel disease. Front Cell Infect Microbiol 2022; 12: 733992.
10.
Federici S, Kredo-Russo S, Valdés-Mas R, et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation. Cell 2022; 185: 2879-98.e24.
11.
Kotunia A, Pietrzak P, Guilloteau P, et al. Butyric acid in gastrointestinal tract. Gastroenterology Rev 2010; 5: 117-22.
12.
Banasiewicz T, Borycka-Kiciak K, Dobrowolska-Zachwieja A, et al. Clinical aspects of sodium butyrate application in dietary treatment of bowel diseases. Gastroenterology Rev 2010; 5: 329-34.
13.
Skrzydło-Radomańska B. Application of butyric acid preparations in clinical practice. Lekarz POZ 2019; 5: 67-74.
14.
Hamer HM, Jonkers D, Venema K, et al. The role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-19.
15.
Scheppach W, Bartram P, Richter A, et al. Effect of short-chain fatty acids on the human colonic mucosa in vitro. J Parent Enteral Nutr 1992; 16: 43-8.
16.
Singh N, Gurav A, Sivaprakasam S, Brady E, et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 2014; 40: 128-39.
17.
Furusawa Y, Obata Y, Fukuda S, et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-50.
18.
Arpaia N, Campbell C, Fan X, Dikiy S, et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 2013; 504: 451-5.
19.
Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1b, and nuclear factor kB in trinitrobenzene sulphonic acid–induced colitis in rats. Postgrad Med J 2006; 82: 130-5.
20.
Jobin C, Balfour Sartor R. The IkB/NF-kB system: a key determinant of mucosal inflammation and protection. Am J Physiol Cell Physiol 2000; 278: C451-62.
21.
Segain JP, Raingeard de la Blétière D, Bourreille A, et al. Butyrate inhibits inflammatory responses through NF-kB inhibition: implications for Crohn’s disease. Gut 2000; 47: 397-403.
22.
Couto MR, Gonçalves P, Magro F, et al. Microbiota-derived butyrate regulates intestinal inflammation: focus on inflammatory bowel disease. Pharmacol Res 2020; 159: 104947.
23.
Czajkowska A, Szponar B. Short-chain fatty acids (SCFA), the products of gut bacteria metabolism and their role in the host. Postęp Higieny Med Dośw 2018; 72: 131-42.
24.
Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between microbiota-derived SCFAs and epithelial HIF augments barrier function. Cell Host Microbe 2015; 17: 662-71.
25.
Recharla N, Geesala R, Shi XZ. Gut microbial metabolite butyrate and its therapeutic role in inflammatory bowel disease: a literature review. Nutrients 2023; 15: 2275.
26.
Louis P, Flint HJ. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol 2017; 19: 29-41.
27.
Rivière A, Selak M, Lantin D, et al. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol 2016; 7: 979.
28.
Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21: 793-8.
29.
Mortensen FV, Clausen MR. Short-chain fatty acids in the human colon: relation to gastrointestinal health and disease. Scand J Gastroenterol Suppl 1996; 216: 132-48.
30.
Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 2011; 17: 1519-28.
31.
Andoh A, Bamba T, Sasaki M. Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. J Parenter Enter Nutr 1999; 23 (5 Suppl): S70-3.
32.
Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005; 128: 1996-2008.
33.
Tarrerias AL, Millecamps M, Alloui A, et al. Short-chain fatty acid enemas fail to decrease colonic hypersensitivity and inflammation in TNBS-induced colonic inflammation in rats. Pain 2002; 100: 91-7.
34.
Vanhoutvin SA, Troost FJ, Kilkens TO, et al. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21: 952-76.
35.
Bajka BH, Clarke JM, Topping DL, et al. Butyrylated starch increases large bowel butyrate levels and lowers colonic smooth muscle contractility in rats. Nutr Res 2010; 30: 427-34.
36.
Bultman SJ. Interplay between diet, gut microbiota, epigenetic regulation, and colorectal cancer. Nat Rev Cancer 2017; 17: 652-69.
37.
McNabney SM, Henagan TM. Short-chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. Nutrients 2017; 9: 1348.
38.
Wong JMW, de Souza R, Kendall CWC, et al. Colonic health: fermentation and short-chain fatty acids. Cancer Letters 2005; 221: 133-47.
39.
Xi Y, Jing Z, Wei W, et al. Inhibitory effect of sodium butyrate on colorectal cancer cells and construction of the related molecular network. BMC Cancer 2021; 21: 127.
40.
Tang Y, Chen Y, Jiang H, et al. G-protein-coupled receptor for short-chain fatty acids suppresses colon cancer. Int J Cancer 2011; 128: 847-56.
41.
Venegas DP, Marjorie K, Landskron G, et al. Short-chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontn Immunol 2019; 10: 277.
42.
Banasiewicz T, Borycka-Kiciak K, Kiciak A, et al. Kwas masłowy w zapaleniach jelit. Gastroenterology Rev 2010; 5: 251-7.
43.
Breuer RI, Buto SK, Christ ML, et al. Rectal irrigation with short-chain fatty acids for distal ulcerative colitis: preliminary report. Dig Dis Sci 1991; 36: 185-7.
44.
Scheppach W, Sommer H, Kirchner T, et al. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103: 51-6.
45.
Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994; 89: 179-83.
46.
Vernia P, Cittadini M, Caprilli R, et al. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995; 40: 305-7.
47.
Vernia P, Marcheggiano A, Caprilli R, et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995; 9: 309-13.
48.
Patz J, Jacobsohn WZ, Gottschalk-Sabag S, et al. Treatment of refractory distal ulcerative colitis with short-chain fatty acid enemas. Am J Gastroenterol 1996; 91: 731-4.
49.
Scheppach W, German Austrian SCFA Study Group. Treatment of distal ulcerative colitis with short-chain fatty acid enemas: a placebo-controlled trial. Dig Dis Sci 1996; 41: 2254-9.
50.
Steinhart AH, Hiruki T, Brzezinski A, et al. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 1996; 10: 729-36.
51.
Breuer RI, Soergel KH, Lashner BA, et al. Short-chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo-controlled trial. Gut 1997; 40: 485-91.
52.
Lührs H, Gerke T, Müller JG, et al. Butyrate inhibits NF-kB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol 2002; 37: 458-66.
53.
Vernia P, Annese V, Bresci G, et al. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. Eur J Clin Investig 2003; 33: 244-8.
54.
Vernia P, Monteleone G, Grandinetti G, et al. Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. Dig Dis Sci 2000; 45: 976-81.
55.
Assisi RF, GISDI Study Group. Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-to-moderate activity: results of a multicentre pilot study. Minerva Gastroenterol Dietol 2008; 54: 231-8.
56.
Vernero M, De Blasio F, Ribaldone DG, et al. The usefulness of microencapsulated sodium butyrate add-on therapy in maintaining remission in patients with ulcerative colitis: a prospective observational study. J Clin Med 2020; 9: 3941.
57.
Kaczmarczyk O, Dąbek-Drobny A, Woźniakiewicz M, et al. Altered fecal short-chain fatty acid profile as a potential marker of disease activity in patients with ulcerative colitis and Crohn’s disease: a pilot study. Pol Arch Intern Med 2022; 132: 16254.
58.
Firoozi D, Masoumi SJ, Mohammad-Kazem Hosseini Asl S, et al. Effects of short-chain fatty acid–butyrate supplementation on expression of circadian-clock genes, sleep quality, and inflammation in patients with active ulcerative colitis: a double-blind randomized controlled trial. Lipids Health Dis 2024; 23: 216.
59.
Karlowicz K, Lewandowski K, Kaniewska M, et al. Efficacy of microencapsulated sodium butyrate as add-on therapy in inducing remission in patients with mild-to-moderate ulcerative colitis: results from a multicenter, double-blind, randomized, placebo-controlled study. Med Sci Monitor 2025; 31: e948912.
60.
Karłowicz K, Lewandowski K, Domżał-Magrowska D, et al. Fecal butyric acid as a predictive biomarker of endoscopic remission in inflammatory bowel disease: a multicenter prospective study. Gastroenterology Rev 2025; 20: 443-8.
61.
Di Sabatino A, Morera R, Ciccocioppo R, et al. Oral butyrate for mildly to moderately active Crohn’s disease. Aliment Pharmacol Ther 2005; 22: 789-94.
62.
Facchin S, Vitulo N, Calgaro M, et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterol Motil 2020; 32: e13914.
63.
Pietrzak A, Banasiuk M, Szczepanik M, et al. Sodium butyrate effectiveness in children and adolescents with newly diagnosed inflammatory bowel diseases: a randomized placebo-controlled multicenter trial. Nutrients 2022; 14: 3283.
